BACKGROUND: Neonatal jaundice or hyperbilirubinemia is a common occurrence in newborns. Although most cases of neonatal jaundice have a benign course, severe hyperbilirubinemia can lead to kernicterus, which is preventable if the hyperbilirubinemia is identified early and treated appropriately. CONTENT: This review discusses neonatal jaundice and the use of transcutaneous bilirubin (TcB) measurements for identification of neonates at risk of severe hyperbilirubinemia. Such a practice requires appropriate serial testing and result interpretation according to risk level from a nomogram that provides bilirubin concentrations specific for the age of the neonate in hours. In this context, we have evaluated the potential impact on clinical outcome and limitations of TcB methods in current use. SUMMARY: TcB measurement is a viable option in screening neonates to determine if they are at risk for clinically significant hyperbilirubinemia. Total serum bilirubin should be measured by a clinical laboratory if a newborn is shown to be at higher risk for clinically significant hyperbilirubinemia. In addition, external quality assessment to identify biases and operator training issues should be part of any TcB monitoring program.
BACKGROUND:Neonatal jaundice or hyperbilirubinemia is a common occurrence in newborns. Although most cases of neonatal jaundice have a benign course, severe hyperbilirubinemia can lead to kernicterus, which is preventable if the hyperbilirubinemia is identified early and treated appropriately. CONTENT: This review discusses neonatal jaundice and the use of transcutaneous bilirubin (TcB) measurements for identification of neonates at risk of severe hyperbilirubinemia. Such a practice requires appropriate serial testing and result interpretation according to risk level from a nomogram that provides bilirubin concentrations specific for the age of the neonate in hours. In this context, we have evaluated the potential impact on clinical outcome and limitations of TcB methods in current use. SUMMARY:TcB measurement is a viable option in screening neonates to determine if they are at risk for clinically significant hyperbilirubinemia. Total serum bilirubin should be measured by a clinical laboratory if a newborn is shown to be at higher risk for clinically significant hyperbilirubinemia. In addition, external quality assessment to identify biases and operator training issues should be part of any TcB monitoring program.
Authors: Li Wang; Arianne Y K Albert; Benjamin Jung; Keyvan Hadad; Martha E Lyon; Melanie Basso Journal: BMC Pediatr Date: 2017-03-29 Impact factor: 2.125
Authors: Chiara Greco; Iman F Iskander; Salma Z El Houchi; Rinawati Rohsiswatmo; Lily Rundjan; Williams N Ogala; Akinyemi O D Ofakunrin; Luciano Moccia; Nguyen Thi Xuan Hoi; Giorgio Bedogni; Claudio Tiribelli; Carlos D Coda Zabetta Journal: EClinicalMedicine Date: 2018-07-17
Authors: Cristiane Maria Conceição; Maria Fernanda Pellegrino da Silva Dornaus; Maria Aparecida Portella; Alice D Agostini Deutsch; Celso Moura Rebello Journal: Einstein (Sao Paulo) Date: 2014 Jan-Mar